Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Rehabilitation of Breast Cancer Patients [Internet].

Juvet LK, Elvsaas IKØ, Leivseth G, Anker G, Bertheussen GF, Falkmer U, Fors EA, Lundgren S, Oldervoll LM, Thune I, Norderhaug IN.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2009 Mar.

2.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.

3.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

4.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.

5.

Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review.

Fors EA, Bertheussen GF, Thune I, Juvet LK, Elvsaas IK, Oldervoll L, Anker G, Falkmer U, Lundgren S, Leivseth G.

Psychooncology. 2011 Sep;20(9):909-18. doi: 10.1002/pon.1844. Epub 2010 Sep 6. Review.

PMID:
20821803
6.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

7.

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J.

Ann Oncol. 2007 Apr;18(4):694-700. Epub 2007 Feb 13.

PMID:
17301072
8.

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.

Sørlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, Anker G, Akslen LA, Botstein D, Børresen-Dale AL, Lønning PE.

Mol Cancer Ther. 2006 Nov;5(11):2914-8.

9.

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4.

10.

Myocardial perfusion in ST-elevation myocardial infarction treated successfully with primary angioplasty.

Hoffmann P, Halvorsen S, Stensaeth KH, Brekke M, Müller C, Anker GO, Abdelnoor M, Kløw NE.

Scand Cardiovasc J. 2006 Apr;40(2):96-104.

PMID:
16608779
11.

Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G.

Int J Cancer. 2006 Jun 1;118(11):2877-81.

12.
13.

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lønning PE.

Clin Cancer Res. 2003 Nov 15;9(15):5582-8.

14.

Plasmalogens protect unsaturated lipids against UV-induced oxidation in monolayer.

Morandat S, Bortolato M, Anker G, Doutheau A, Lagarde M, Chauvet JP, Roux B.

Biochim Biophys Acta. 2003 Oct 13;1616(2):137-46.

15.
17.

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.

Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, Mella O, Howell A.

Breast Cancer Res Treat. 2001 May;67(2):111-6.

PMID:
11519859
18.

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.

Helle SI, Geisler J, Anker GB, Leirvaag B, Holly JM, Lønning PE.

Br J Cancer. 2001 Jul 20;85(2):147-51.

19.

[Population-related findings and treatment results and clinic variations in the Munich field study of rectal carcinoma].

Engel J, Anker G, Hölzel D, Jauch KW, Roder J.

Zentralbl Chir. 2000;125(12):947-53. German.

PMID:
11190611
20.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N.

Lancet. 2000 Oct 21;356(9239):1384-91. Erratum in: Lancet 2000 Dec 23-30;356(9248):2196.

PMID:
11052580
21.

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G.

Eur J Cancer. 2000 May;36(8):976-82.

PMID:
10885600
22.

Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen.

Love RR, Anker G, Yang Y, Refsum H, Ueland PM, Lønning PE, Lien EA.

Cancer Lett. 1999 Oct 18;145(1-2):73-7.

PMID:
10530772
23.

Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.

Anker GB, Refsum H, Ueland PM, Johannessen DC, Lien EA, Lonning PE.

Clin Chem. 1999 Feb;45(2):252-6.

24.

[Recommendations on the contents of medical reports in rectal carcinoma: II: Physician's letter. Orienting guides in the interdisciplinary patient care process].

Engel J, Reimer B, Anker G, Hölzel D, Staimmer D, Roder J, Jauch KW.

Zentralbl Chir. 1998;123(11):1322-4. German. No abstract available.

PMID:
9880856
25.

[Recommendations on contents of medical reports in rectal carcinoma: I: Surgical report and pathology findings. Orientating aids in interdisciplinary management].

Engel J, Staimmer D, Wiebecke B, Reimer B, Anker G, Hölzel D, Roder J, Jauch KW.

Zentralbl Chir. 1998;123(10):1201-4. German. No abstract available.

PMID:
9848263
26.

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, Dowsett M.

Clin Cancer Res. 1998 Sep;4(9):2089-93.

27.

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmström P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N.

Ann Oncol. 1998 Apr;9(4):403-11.

PMID:
9636831
28.

Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.

Anker GB, Lønning PE, Aakvaag A, Lien EA.

Scand J Clin Lab Invest. 1998 Apr;58(2):103-7.

PMID:
9587161
29.

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women.

Helle SI, Anker GB, Meadows KA, Holly JM, Lønning PE.

Maturitas. 1998 Jan 12;28(3):259-65.

PMID:
9571602
30.

Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine.

Lien EA, Anker G, Lønning PE, Refsum H, Ueland PM.

Biochem Soc Trans. 1997 Feb;25(1):33-5. Review. No abstract available.

PMID:
9056838
31.
32.
33.

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.

Lien EA, Anker G, Ueland PM.

J Steroid Biochem Mol Biol. 1995 Nov;55(2):229-31.

PMID:
7495702
34.
35.

Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography.

Lien EA, Anker G, Lønning PE, Ueland PM.

Ther Drug Monit. 1995 Jun;17(3):259-65.

PMID:
7624922
36.

Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen.

Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA.

Int J Cancer. 1995 Jan 27;60(3):365-8.

PMID:
7829246
37.

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

Lønning PE, Helle SI, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K.

Clin Endocrinol (Oxf). 1995 Jan;42(1):23-30. Erratum in: Clin Endocrinol (Oxf) 1995 Dec;43(6):772.

PMID:
7534218
38.

Diethyldithiocarbamate (ditiocarb sodium) effect on arachidonic acid metabolism in human mononuclear cells. Glutathione peroxidase-like activity.

Hosni M, Meskini N, Prigent AF, Anker G, Joulain C, el Habib R, Lagarde M.

Biochem Pharmacol. 1992 Mar 17;43(6):1319-29.

PMID:
1314059
39.

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

Lien EA, Anker G, Lønning PE, Solheim E, Ueland PM.

Cancer Res. 1990 Sep 15;50(18):5851-7.

40.

Concanavalin A stimulates the Rolipram-sensitive isoforms of cyclic nucleotide phosphodiesterase in rat thymic lymphocytes.

Valette L, Prigent AF, Némoz G, Anker G, Macovschi O, Lagarde M.

Biochem Biophys Res Commun. 1990 Jun 29;169(3):864-72.

PMID:
2163636
41.

Constructional constraint and its ecomorphological implications.

Barel CD, Anker GC, Witte F, Hoogerhoud RJ, Goldschmidt T.

Acta Morphol Neerl Scand. 1989;27(1-2):83-109.

PMID:
2816530
42.

Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors.

Prigent AF, Fougier S, Nemoz G, Anker G, Pacheco H, Lugnier C, Lebec A, Stoclet JC.

Biochem Pharmacol. 1988 Oct 1;37(19):3671-81.

PMID:
2845994
43.

Functional aspects of four bar systems as models for mouth-opening mechanisms in teleost fishes.

Barel CD, Berkhoudt H, Anker GC.

Acta Morphol Neerl Scand. 1975 Nov;13(3):228-9. No abstract available.

PMID:
1211227
44.

An epoxy resin embedding technique for large objects.

Anker GC, Scheers-Dubbeldam K, Noorlander C.

Stain Technol. 1974 Jul;49(4):183-8. No abstract available.

PMID:
4135913
45.

An apparatus for direct x-ray cinematography exemplified by analysis of some respiratory movements in Gasterosteus aculeatus.

Anker GC, Simons J, Dullemeijer P.

Experientia. 1967 Jan 15;23(1):74-7. No abstract available.

PMID:
6031582

Supplemental Content

Support Center